Fillable TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (USPTO)

Fill Online, Printable, Fillable, Blank TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (USPTO) Form

Use Fill to complete blank online USPTO (DC) pdf forms for free. Once completed you can sign your fillable form or send for signing. All forms are printable and downloadable.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (USPTO)

On average this form takes 17 minutes to complete

The TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (USPTO) form is 3 pages long and contains:

  • 0 signatures
  • 35 check-boxes
  • 53 other fields

Country of origin: US
File type: PDF

U.S.A. forms for USPTO

BROWSE USPTO (DC) FORMS

Related forms
Fill has a huge library of thousands of forms all set up to be filled in easily and signed.
Fill in your chosen form
Sign the form using our drawing tool
Send to someone else to fill in and sign.
find another form
 
PTO-1390 (10-20)
Approved for use through 10/31/2022. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371
Attorney Docket No.
U.S. Application No. (if known, see 37 CFR 1.5)
International Application No.
International Filing Date
Priority Date Claimed
Title of Invention
First Named Inventor
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.
1.
This is an express request to begin national examination procedures (35 U.S.C. 371(f)). NOTE: The express request under
35 U.S.C. 371(f) will not be effective unless the requirements under 35 U.S.C. 371(c)(1), (2), and (4) for payment of the basic
national fee, copy of the International Application and English translation thereof (if required), and the oath or declaration of the
inventor(s) have been received.
2.
A copy of the International Application (35 U.S.C. 371(c)(2)) is attached hereto (not required if the International Application was
previously communicated by the International Bureau or was filed in the United States Receiving Office (RO/US)).
3.
An English language translation of the International Application (35 U.S.C. 371(c)(2))
a.
is attached hereto.
b.
has been previously submitted under 35 U.S.C. 154(d)(4).
4.
An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4))
a.
is attached.
b.
was previously filed in the international phase under PCT Rule 4.17(iv).
Items 5 to 8 below concern amendments made in the international phase.
PCT Article 19 and 34 amendments
5.
Amendments to the claims under PCT Article 19 are attached (not required if communicated by the International Bureau)
(35 U.S.C. 371(c)(3)).
6.
English translation of the PCT Article 19 amendment is attached (35 U.S.C. 371(c)(3)).
7.
English translation of annexes (Article 19 and/or 34 amendments only) of the International Preliminary Examination Report is
attached (35 U.S.C. 371(c)(5)).
Cancellation of amendments made in the international phase
8a.
Do not enter the amendment made in the international phase under PCT Article 19.
8b.
Do not enter the amendment made in the international phase under PCT Article 34.
NOTE: A proper amendment made in English under Article 19 or 34 will be entered in the U.S. national phase application absent a clear
instruction from applicant not to enter the amendment(s).
The following items 9 to 17 concern a document(s) or information included.
9.
An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
10.
A preliminary amendment.
11.
An Application Data Sheet under 37 CFR 1.76.
12.
A substitute specification. NOTE: A substitute specification cannot include claims. See 37 CFR 1.125(b).
13.
A power of attorney and/or change of address letter.
14.
A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.3 and 37 CFR 1.821-1.825 (not required if
sequence listing in text format was indicated on the PCT Request as part of the International Application and the sequence listing
was published as part of the international application).
15.
Assignment papers (cover sheet and document(s)). Name of Assignee: _____________________________________________
_______________________________________________________________________________________________________
16.
37 CFR 3.73(c) Statement (when there is an Assignee).
This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file
(and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15
minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual
case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information
Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED
FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
PTO-1390 (10-20)
Approved for use through 10/31/2022. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
U.S. APPLN. No. (if known – see 37 CFR 1.5)
INTERNATIONAL APPLICATION No. ATTORNEY DOCKET No.
17.
Other items or information:
The following fees have been submitted.
18.
Basic national fee (37 CFR 1.492(a)) ………………………………………………….……………….. $320
CALCULATIONS
$
19.
Examination fee (37 CFR 1.492(c))
• If the written opinion prepared by ISA/US or the international preliminary examination report
prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)………….. $0
•
All other situations ……………………………………………….………………………………….. $800
$
20.
Search fee (37 CFR 1.492(b))
• If the written opinion prepared by ISA/US or the international preliminary examination report
prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)………….. $0
• Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as
an International Searching Authority ..………………………………………………………….…. $140
• International Search Report prepared by an ISA other than the US and provided to the Office or
previously communicated to the US by the IB……………………………………….……………. $540
• All other situations ...……………………………………………….……………...…….…………... $700
$
TO
TAL OF 18, 19, and 20 =
$
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing
in compliance with 37 CFR 1.821(c) or (e) in an electronic medium or computer program listing in an
electronic medium) (37 CFR 1.492(j)).
Fee for each additional 50 sheets of paper or fraction thereof …………………………….………... $420
$
Total Sheets Extra Sheets
Number of each additional 50 or fraction
thereof (round up to a whole number)
RATE
- 100 = / 50 =
x $420
Surcharge for furnishing any of the search fee, examination fee, or the oath or declaration after the date of
commencement of the national stage (37 CFR 1.492(h))…………………………………….……………….. $160
$
CLAIMS NUMBER FILED NUMBER EXTRA RATE
Total claims - 20 =
x $100
$
Independent claims - 3 =
x $480
$
MULT
IPLE DEPENDENT CLAIM(S) (if applicable)
+ $860
$
Fee for submission of Sequence Listing text file of 300 MB to 800 MB (37 CFR 1.21(o)(1))…….………… $1,060
$
Fee for submission of Sequence Listing text file of more than 800 MB (37 CFR 1.21(o)(2))……………….$10,500
$
Proc
essing fee for furnishing the English translation later than 30 months from the earliest claimed priority date
(37 CFR 1.492(i))………………………………………………………..…………………………………………...$140 +
$
TOTAL OF ABOVE CALCULATIONS =
$
Applicant asserts small entity status.
See 37 CFR 1.27. Fees above are reduced by ½.
Applicant certifies micro entity status.
See 37 CFR 1.29. Fees above are reduced by ¾.
Applicant must attach form PTO/SB/15A or B or equivalent.
TOTAL NATIONAL FEE =
$
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an
appropriate cover sheet (37 CFR 3.28, 3.31)…………..…………………………………… $50.00 per property +
$
TOTAL FEES ENCLOSED =
$
[Page 2 of 3]
PTO-1390 (10-20)
Approved for use through 10/31/2022. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
a.
A check in the amount of $_____________________ to cover the above fees is enclosed.
b.
Please charge my Deposit Account No. ___________________ in the amount of $____________________ to cover the above fees.
c.
The Director is hereby authorized to charge additional fees which may be required, or credit any overpayment, to Deposit Account
No. ___________________ as follows:
i.
any required fee.
ii.
any required fee except for excess claims fees required under 37 CFR 1.492(d) and (e) and multiple dependent claim fee
required under 37 CFR 1.492(f).
d.
Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not
be included on this form. Provide credit card information and authorization on PTO-2038. The PTO-2038 should only be mailed or
faxed to the USPTO. However, when paying the basic national fee, the PTO-2038 may NOT be faxed to the USPTO.
ADVISORY: If filing by EFS-Web, do NOT attach the PTO-2038 form as a PDF along with your EFS-Web submission. Please be
advised that this is not recommended and by doing so your credit card information may be displayed via PAIR. To protect your
information, it is recommended to pay fees online by using the electronic payment method.
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be
filed and granted to restore the International Application to pending status.
Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications
This application (1) claims priority to or the benefit of an application filed before March 16, 2013, and (2) also contains, or contained at
any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.
NOTE 1: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be
examined under the first inventor to file provisions of the AIA.
NOTE 2: A U.S. national stage application may not claim priority to the international application of which it is the national phase. The filing
date of a U.S. national stage application is the international filing date. See 35 U.S.C. 363.
Correspondence Address
The address associated with Customer Number: _______________________ OR Correspondence address below
Name
Address
City State Zip Code
Country Telephone
Email
Signature Date
Name
(Print/Type)
Registration No.
(Attorney/Agent)
[Page 3 of 3]
Privacy Act Statement
The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of
the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2)
furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the
U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or
patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to
process and/or examine your submission, which may result in termination of proceedings or abandonment of the
application or expiration of the patent.
The information provided by you in this form will be subject to the following routine uses:
1. The information on this form will be treated confidentially to the extent allowed under the Freedom of
Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may
be disclosed to the Department of Justice to determine whether disclosure of these records is required by the
Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
request involving an individual, to whom the record pertains, when the individual has requested assistance from
the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
need for the information in order to perform a contract. Recipients of information shall be required to comply
with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of
records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property
Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General
Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency’s
responsibility to recommend improvements in records management practices and programs, under authority of
44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing
inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of
the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a
record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record
was filed in an application which became abandoned or in which the proceedings were terminated and which
application is referenced by either a published application, an application open to public inspection or an issued
patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
Download
Save PDF to desktop
Email
Email completed PDF
Send for Signing
Email for others to sign
Print
Print document
Choose a Field
Click on a field and
select the person that should complete it
Want to add a signature?
You can add a signature field
and assign it to someone else
to sign
Choose a Field
Click on a field and
select the person that should complete it

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATEDELECTED OFFICE (USPTO)

This document is locked as it has been sent for signing.

You have successfully completed this document.

Other parties need to complete fields in the document. You will recieve an email notification when the document has been completed by all parties.

This document has been signed by all parties.

Completed 17 July 2021

Message

View Audit Log
Print With Audit Log
Duplicate Document